Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world single-arm study of gemcitabine + nab-paclitaxel for locally advanced or metastatic pancreatic cancer
ChiCTR1900027729Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and paclitaxel in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC), sponsored by West China Hospital of Sichuan University. Primary endpoint: overall survival. Started Nov 2019; status: recruiting.
02
Drugs
gemcitabinepaclitaxel
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR1900027729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027729.